We are live on ! Find out more
BMY icon

Bristol-Myers Squibb

1,523 hedge funds and large institutions have $63.3B invested in Bristol-Myers Squibb in 2016 Q3 according to their latest regulatory filings, with 110 funds opening new positions, 663 increasing their positions, 548 reducing their positions, and 147 closing their positions.

New
Increased
Maintained
Reduced
Closed

21% more repeat investments, than reductions

Existing positions increased: 663 | Existing positions reduced: 548

3.14% less ownership

Funds ownership: 73.94%70.8% (-3.1%)

3% less funds holding

Funds holding: 1,5771,523 (-54)

17% less call options, than puts

Call options by funds: $1.15B | Put options by funds: $1.38B

25% less first-time investments, than exits

New positions opened: 110 | Existing positions closed: 147

30% less capital invested

Capital invested by funds: $90.9B → $63.3B (-$27.6B)

55% less funds holding in top 10

Funds holding in top 10: 11049 (-61)

Holders
1,523
Holders Change
-54
Holders Change %
-3.42%
% of All Funds
40.62%
Holding in Top 10
49
Holding in Top 10 Change
-61
Holding in Top 10 Change %
-55.45%
% of All Funds
1.31%
New
110
Increased
663
Reduced
548
Closed
147
Calls
$1.15B
Puts
$1.38B
Net Calls
-$227M
Net Calls Change
-$366M
Name Holding Trade Value Shares
Change
Change in
Stake
QIM
301
Quantitative Investment Management
Virginia
$11.3M +$7.41M +115,400 +122%
QAM
302
QCI Asset Management
New York
$11.2M +$169K +2,634 +1%
PAG
303
Private Advisor Group
New Jersey
$11.2M +$417K +6,491 +3%
CC
304
Cornerstone Capital
California
$11.2M -$205K -3,185 -2%
B
305
BP
United Kingdom
$11.1M -$193K -3,000 -1%
AHB
306
Abner Herrman & Brock
New Jersey
$11M +$319K +4,961 +2%
CCP
307
Clough Capital Partners
Massachusetts
$11M +$2.24M +34,942 +21%
N
308
Nuveen
North Carolina
$11M -$200K -3,116 -2%
SF
309
Synovus Financial
Georgia
$10.9M -$1.79M -27,941 -12%
KLWA
310
Kelly Lawrence W & Associates
California
$10.7M +$10.5M +163,315 +454%
CDH
311
Charles D. Hyman
$10.7M -$51.4K -800 -0.4%
MOACM
312
Mutual of America Capital Management
New York
$10.6M +$173K +2,696 +1%
EB
313
Eastern Bank
Massachusetts
$10.6M +$11.3M +175,781 +847%
CTC
314
Central Trust Company
Missouri
$10.4M +$661K +10,289 +6%
SIP
315
Stoneridge Investment Partners
Pennsylvania
$10.4M +$12.4M +193,005 New
CIC
316
Canal Insurance Company
South Carolina
$10.3M +$3.85M +60,000 +46%
RIG
317
Roosevelt Investment Group
New York
$10.3M -$2.62M -40,735 -18%
CCM
318
Cadence Capital Management
Massachusetts
$10.3M +$12.2M +190,283 New
Envestnet Asset Management
319
Envestnet Asset Management
Illinois
$10.2M -$2.42M -37,730 -17%
BFM
320
Boston Financial Management
Massachusetts
$10.1M -$479K -7,458 -4%
Baillie Gifford & Co
321
Baillie Gifford & Co
United Kingdom
$9.91M
Calamos Advisors
322
Calamos Advisors
Illinois
$9.82M +$1.63M +25,374 +16%
UB
323
UMB Bank
Missouri
$9.79M -$1.33M -20,641 -10%
MC
324
Muhlenkamp & Co
Pennsylvania
$9.72M -$65.8K -1,024 -0.6%
GIP
325
Granite Investment Partners
California
$9.67M -$349K -5,435 -3%

BMY Hedge Fund Activity: Q3 2016 in Review

1,523 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Bristol-Myers Squibb (BMY) for Q3 2016, worth a combined $63.3B — down 30% from $90.9B a quarter earlier.

Sellers outnumbered buyers: 147 funds closed out of BMY and 110 opened new positions — a net loss of 37 holders — while 548 trimmed existing stakes and 663 added.

The largest buyer was Wellington Management Group, adding an estimated $437M. The largest seller was T. Rowe Price Associates, cutting an estimated $1.74B.

  • 1,523 institutional investors held Bristol-Myers Squibb (BMY) as of Q3 2016, down from 1,577 in Q2 2016.
  • Funds reported $63.3B of Bristol-Myers Squibb stock for Q3 2016, down 30% quarter-over-quarter.
  • 110 funds opened new Bristol-Myers Squibb positions in Q3 2016 and 147 closed out, a net change of -37 holders.
  • The largest Bristol-Myers Squibb buyer in Q3 2016 was Wellington Management Group, an estimated $437M added.
  • The largest Bristol-Myers Squibb seller in Q3 2016 was T. Rowe Price Associates, an estimated $1.74B sold.

Based on aggregated 13F filings for Q3 2016.